Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

POTS Treatment: Scientifically & Medically Proven • MyHeart

PDF) 2015 Heart Rhythm Society Expert Consensus Statement on the

Frontiers Chronic Treatment with Ivabradine Does Not Affect

Frontiers Chronic Treatment with Ivabradine Does Not Affect

Karsten HEUSSER, Senior Physician Scientist

Frontiers Chronic Treatment with Ivabradine Does Not Affect

PDF) 2015 Heart Rhythm Society Expert Consensus Statement on the

Cardiac Origins of the Postural Orthostatic Tachycardia Syndrome

Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine